Shares of MorphoSys AG Unsponsored ADR (NYSE:MOR) have been assigned an average broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus target price of $37.17 for the company and are anticipating that the company will post ($0.38) EPS for the current quarter, according to Zacks. Zacks has also assigned MorphoSys an industry rank of 58 out of 255 based on the ratings given to its competitors.
Shares of MOR stock traded up $0.31 during mid-day trading on Wednesday, hitting $31.85. The stock had a trading volume of 300 shares, compared to its average volume of 64,043. The company’s 50-day simple moving average is $28.08 and its 200-day simple moving average is $27.52. MorphoSys has a fifty-two week low of $22.46 and a fifty-two week high of $31.96.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
See Also: What is a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.